September 28, 2021
Bangalore (Reuters)-Indian drug regulators on Tuesday allowed vaccine maker Serum Institute to enroll children aged 7 to 11 years in the COVID-19 vaccine trial of US pharmaceutical company Novabacs.
South Asian countries have already administered more than 870 million doses to adults out of a population of approximately 1.4 billion.
“After detailed deliberation, the Commission recommended that subjects aged 7 to 11 years be enrolled according to the protocol,” said the Central Drugs Standard Control Organization’s Subject Expert Panel.
The Serum Institute is already testing the COVID-19 vaccine Covovax. This is a domestically produced version of Novavax Shot, presenting safety data for the first 100 participants in a group aged 12-17.
The Novavax vaccine has not yet been approved by the Indian health authorities. Earlier this month, Serum Institute chief Adar Poonawalla said he hopes Covovax will be approved by people under the age of 18 in January or February next year.
So far, in India, only the DNACOVID-19 vaccine from the pharmaceutical company Zydus Cadila has received an emergency use authorization for use in adults and children over the age of 12.
(Report by Anuron Kumar Mitra in Bangalore; edited by Arun Koyyur and Subhranshu Sahu)
India allows the Serum Institute to enroll children aged 7-11 years in the Novavax COVID-19 vaccine trial
Source link India allows the Serum Institute to enroll children aged 7-11 years in the Novavax COVID-19 vaccine trial